Ionis Pharmaceuticals, Inc. (IONS) drops 8.7% after trial miss
Ionis Pharmaceuticals, Inc. (IONS) drops sharply after a Phase 3 ATTR-CM trial for eplontersen missed its primary endpoint, pressuring the stock on heavy volume. The setback trims a key growth opportunity, even as the company continues to show solid commercial execution and a strong earnings track record.
Ionis Pharmaceuticals, Inc. (IONS) drops sharply after the Phase 3 CARDIO-TTRansform trial for eplontersen missed its primary endpoint in ATTR-CM. The setback weakens a major growth thesis for WAINUA and forces investors to reset expectations for future revenue and royalty upside, even though Ionis still has a commercial-stage business and a broad RNA pipeline.
Ionis Pharmaceuticals, Inc. (IONS) drops sharply today as investors react to a high-impact clinical setback tied to one of the company’s most important late-stage growth programs. At 12:04 p.m. ET, IONS traded at $58.65, down 8.74%, while volume ran at 2.4x its 200-day average, a sign that this is a catalyst-driven repricing rather than routine biotech volatility.
Key Takeaways
IONS is falling on above-average volume after Ionis and AstraZeneca said the Phase 3 CARDIO-TTRansform trial of eplontersen missed its primary endpoint in ATTR-CM.
The failed study removes a major expansion opportunity for WAINUA beyond hereditary ATTR polyneuropathy, which cuts into a key part of the bullish pipeline story.
The selloff comes despite solid recent execution elsewhere, including a 7-for-7 earnings beat streak and unchanged FY26 outlook reiterated on July 10.
Analysts moved fast after the news, with price targets cut by firms including Morgan Stanley, Canaccord, Barclays, Jefferies, Needham, and Raymond James.
For investors, the issue is not Ionis’s entire platform but the loss of a large cardiology upside case in a market where Alnylam already has an approved ATTR-CM therapy.
What Is Behind Ionis Pharmaceuticals, Inc.'s Selloff Today
The main reason IONS stock is down today is straightforward. On July 9, Ionis and AstraZeneca announced that the Phase 3 CARDIO-TTRansform trial of eplontersen in transthyretin-mediated amyloid cardiomyopathy, or ATTR-CM, failed to meet its primary endpoint.
More specifically, the study did not show a statistically significant benefit versus placebo on the composite endpoint of cardiovascular mortality and recurrent cardiovascular events. Ionis said a pre-specified monotherapy subgroup showed a nominally significant result, and safety remained favorable. However, markets rarely reward a missed primary endpoint with patience. In biotech, that is the scoreboard.
The timing also fits the move. Reports on July 9 cited IONS down about 21.8% premarket, while other coverage said the stock slumped roughly 19% after the announcement. Today’s continued weakness shows that investors are still resetting assumptions around the commercial value of eplontersen.
There is also a second layer to the selloff. On July 10, Roche said it is discontinuing clinical studies for two Huntington’s disease therapies developed with Ionis. That headline added pressure, but it looks more like fuel on an already burning fire. The primary break in sentiment came from the ATTR-CM Phase 3 miss.
Why the WAINUA and Eplontersen Trial Failure Matters So Much
This was not a minor pipeline update. CARDIO-TTRansform was one of Ionis’s most important 2026 milestones and a major chance to expand eplontersen, marketed as WAINUA, beyond its approved use in hereditary ATTR polyneuropathy.
That expansion mattered because ATTR-CM is a commercially meaningful market. It also mattered because competition is already real. Alnylam (ALNY) has an approved ATTR-CM label for Amvuttra and has been building momentum in the space. When Ionis lost this readout, the market did not just mark down one trial. It marked down Ionis’s ability to win a larger share of a valuable disease area.
For a company like Ionis, partnered programs are part of the economic engine. A failed expansion study can reduce future milestone payments, trim royalty expectations, and weaken the long-term revenue mix. That is why a single trial miss can hit valuation so hard even when the company still has approved products and a broader platform.
The broader market readthrough backed that up. AstraZeneca also sold off on the news, while reports said Alnylam and BridgeBio were seen as relative winners. That kind of peer reaction reinforces that this was a meaningful competitive event, not just a bad headline.
Get AI research on any stock
Instant reports, daily intelligence, and an AI analyst in your pocket.
How Ionis Pharmaceuticals, Inc.'s Financial Setup Looks After the Drop
The stock reaction is severe, but Ionis is not a single-asset biotech. The company has a $9.69B market cap and already sells multiple medicines, including TRYNGOLZA, DAWNZERA, WAINUA, and SPINRAZA. Its business model combines commercial products, royalty streams, and partnered development programs.
Recent earnings execution had actually been solid. Ionis has beaten EPS estimates in seven straight reported quarters. On April 29, 2026, the company posted EPS of -$0.30 versus a -$0.77 estimate, a 61% surprise. It also reiterated its FY26 outlook on July 10, unchanged from the projections first issued in April.
That contrast matters. The selloff is not being driven by a collapsing income statement or a guidance cut. Instead, the market is discounting future pipeline value. In biotech, that future value often carries more weight than trailing earnings, especially when a late-stage program targets a large expansion market.
Valuation also looks different after the move. With IONS at $58.65 versus a 52-week high of $86.74, the stock has given back a large chunk of prior optimism. Yet Wall Street has not abandoned the name. The analyst consensus still sits at Buy, with 19 Buys, 12 Holds, and no Sells. Even so, price targets moved lower fast after the trial miss, including Morgan Stanley to $110 from $130, Canaccord to $95 from $110, Barclays to $90, Jefferies to $90, Needham to $86 from $105, and Raymond James to $87 from $104.
What the Ionis Stock Decline Means for Investors Now
The practical takeaway is that Ionis now looks more like a platform story with a damaged near-term catalyst slate than a clean cardiometabolic expansion winner. That does not erase the company’s RNA-targeted medicine franchise, but it does force a reset in how much investors are willing to pay for future pipeline upside.
For shorter-term traders, the combination of an 8.74% drop and 2.4x relative volume shows conviction behind the move. That often means the stock needs time to build a new base, especially after a late-stage trial failure triggers several same-day and next-day price target cuts.
For longer-term investors, the more useful distinction is between platform damage and asset damage. The evidence points to asset damage. Ionis still has marketed products, a commercial-stage profile, and a broad RNA medicine pipeline. However, the loss of the ATTR-CM opportunity lowers the ceiling on one of the company’s more visible growth paths.
Ionis (IONS) drops today because a major Phase 3 eplontersen study in ATTR-CM missed its primary endpoint, and the market is repricing that lost opportunity in real time. The company still has depth beyond one program, but this setback hits a valuable expansion story, which is why the volume is elevated and the reaction is so sharp.
IONS is falling because Ionis and AstraZeneca said the Phase 3 CARDIO-TTRansform trial of eplontersen missed its primary endpoint in ATTR-CM. That removes a major expansion opportunity for the drug and led investors to reprice future growth expectations lower.
+Should I buy IONS stock now?
The stock may appeal to long-term investors who believe in Ionis’s broader platform, but the near-term setup is still pressured by the trial failure and analyst target cuts. Waiting for the stock to stabilize may be the more prudent move.
+Did Ionis Pharmaceuticals miss earnings?
No, the selloff is not being driven by an earnings miss or a guidance cut. Ionis has recently posted solid execution, but the market is focused on the failed late-stage ATTR-CM trial.
+What does the trial failure mean for Ionis investors?
It lowers the ceiling on one of Ionis’s most important growth stories and reduces the chance of a larger commercial opportunity for WAINUA. The company still has marketed products and a pipeline, but investors are likely to value the stock more conservatively now.
▌The Daily Briefing · Free
A new stock idea, every evening.
One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.
▌The Full Report
Want the full picture on IONS?
The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.
